Interstitial Lung Disease
Conditions
Interventions
In the standard-dose group, one tablet of sulfamethoxazole-trimethoprim (sulfamethoxazole 400 mg / trimethoprim 80 mg) is administered orally once daily. Treatment is continued during corticosteroid t
Sponsors
Sapporo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 20 years or older with interstitial lung disease receiving corticosteroid therapy.
Exclusion criteria
Exclusion criteria: Patients with HIV infection, a history of organ transplantation, or those who are pregnant or breastfeeding, as well as patients planning pregnancy during the study period. Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2) will be assigned to the renal impairment group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of treatment discontinuation due to adverse events and incidence of severe adverse events (Grade 3 or higher according to CTCAE v5.0) | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of Pneumocystis jirovecii pneumonia (PCP) Time to treatment discontinuation or occurrence of severe adverse events (Grade 3 or higher) Incidence of subclinical PCP and subsequent management | — |
Countries
Japan
Contacts
Public ContactYusuuke Tanaka
Sapporo Medical University Department of Respiratory Medicine and Allergology
Outcome results
None listed